Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director ...

Keros Therapeutics, Inc. (KROS) shares soared 5.1% in the last trading session to close at $11.41. The move was backed by solid volume with far more shares changing hands than in a normal session.

Keros Therapeutics’ KROS shares jumped 18.5% yesterday following an announcement that it is exploring strategic options, including a potential sale of the business. To aid the decision process ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp ...

Short interest in Keros Therapeutics Inc (NASDAQ:KROS) increased during the last reporting period, rising from 4.41M to 5.27M. This put 20.31% of the company's publicly available shares short.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Keros Therapeutics, Inc. (KROS) came out with quarterly earnings of $3.62 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $1.21 per share a year ...

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...